ABIONYX Pharma: Press Release
03 Februar 2023 - 8:44PM
Business Wire
Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - eligible for PEA
PME), a new generation biotech company dedicated to the
discovery and development of innovative therapies for patients,
announced today that it has been informed by TVM Capital of the
total sale of their shares on the market due to the liquidation of
their funds that have reached maturity.
ABIONYX Pharma would like to thank TVM Capital funds for their
commitment to the company since 2006 and for their support in the
development of CER-001, one of the most advanced bioproduct and the
only natural recombinant apoA-I in the world.
About ABIONYX Pharma ABIONYX Pharma is a new generation
biotech company that aims to contribute to health through
innovative therapies in indications where there is no effective or
existing treatment, even the rarest ones. Thanks to its partners in
research, medicine, biopharmaceuticals and shareholding, the
company innovates on a daily basis to propose drugs for the
treatment of renal and ophthalmological diseases, or new HDL
vectors used for targeted drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230203005409/en/
NewCap Investor Relations Nicolas Fossiez Louis-Victor
Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
Von Apr 2023 bis Apr 2024